A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05353257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
Study identification
- NCT ID
- NCT05353257
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 511 participants
Conditions and interventions
Conditions
Interventions
- HLX10 Drug
- carboplatin/cisplatin-etoposide Drug
- Thoracic radiotherapy Radiation
- Placebo Drug
- Prophylactic Cranial Irradiation (PCI) Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 17, 2022 (Actual)
- Primary completion
- Jun 30, 2026 (Estimated)
- Completion
- May 30, 2028 (Estimated)
- Last update posted
- Jan 13, 2026
2022 – 2028
United States locations
- U.S. sites
- 31
- U.S. states
- 15
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OPN-Glendale | Arcadia | California | 91007 | — |
| OPN-Los Alamitos | Los Alamitos | California | 90720 | — |
| Southern California Permanente Group | Los Angeles | California | 90034 | — |
| Emad Ibrahim, MD, Inc | Redlands | California | 92373 | — |
| Providence Medical Foundation | Santa Rosa | California | 95403 | — |
| Lutheran Medical Center - Cancer Centers of Colorado | Golden | Colorado | 80401 | — |
| Eastern Connecticut Hematology & Oncology Associates | Norwich | Connecticut | 06360 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32257 | — |
| Mid Florida Hematology and Oncology Center | Orange City | Florida | 32763 | — |
| Advent Health Orlando | Orlando | Florida | 32804 | — |
| Napa Research | Pompano Beach | Florida | 33064 | — |
| Kansas University Mediacal Center | Fairway | Kansas | 66205 | — |
| Pontchartrain Cancer Center | Covington | Louisiana | 70433 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Health Partners | Bloomington | Minnesota | 55425 | — |
| Renown Health | Reno | Nevada | 89502 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| New York City Health+HospitalsCorporation Elmhurst Hospital Center | Elmhurst | New York | 11373 | — |
| Northwell Health | Queens | New York | 11040 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Cleveland Clinic Mercy Hospital | Canton | Ohio | 44708 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Tricounty Hematology and Oncology Associates | Massillon | Ohio | 44646 | — |
| Kaiser Permanente Northwest | Portland | Oregon | 97229 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Millennium Research & Clinical Development | Houston | Texas | 77090 | — |
| Pro Research Tools, INC DBA Lumi Research | Kingwood | Texas | 77339 | — |
| The University of Texas - Hope Cancer Center | Tyler | Texas | 75701 | — |
| Innova Schar Cancer Insitute | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05353257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05353257 live on ClinicalTrials.gov.